Last Updated : May 12, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort ascending | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Afinitor | Everolimus | Renal angiomyolipoma associated with tuberous sclerosis complex (TSC) | Do not list | Complete | ||
| Sublinox | Zolpidem tartrate | Insomnia | Do not list | Complete | ||
| Edarbyclor | Azilsartan medoxomil + chlorthalidone | Hypertension | Do not list | Complete | ||
| Picato | Ingenol mebutate | Actinic keratosis | Do not list | Complete | ||
| Botox | OnabotulinumtoxinA | Migraine | Do not list | Complete | ||
| Intuniv XR | Guanfacine hydrochloride | Attention-deficit/hyperactivity disorder (ADHD) | Do not list | Complete | ||
| Neupro | Rotigotine | Parkinson's disease | Do not list | Complete | ||
| Grastek | Phleum pratense | Allergic rhinitis | Do not list | Complete | ||
| Abilify | Aripiprazole | Depression, Major Depressive Disorder | Do not list | Complete | ||
| Nesina | Alogliptin | Diabetes mellitus, type 2 | Do not list | Complete |
Last Updated : May 12, 2024